SC

Suresh Chand Saini

Active Director Director DIN 07652621
DIN 07652621 First appointment Dec 2016 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 7 active board seats
Past companies 1 historical roles
Total affiliations 8 Since Dec 2016
Shareholding value •••• Premium profile

About Suresh Chand Saini

Data last updated:

Suresh Chand Saini is a Director at Alkon Formulation Private Limited (since 2017), Director at Septy Pharmaceuticals Private Limited (since 2022) and Director at Saksham Parenteral Private Limited (since 2026), and holds 4 more current directorships. The companies operate in Pharma, Paper and Wood. The 2 current companies with reported revenue have a combined latest revenue of ₹9.39 Cr; the largest is Alkon Formulation Private Limited at ₹7.74 Cr (FY 2024). Earlier, Suresh Chand Saini was a Director at Almech India Private Limited (from 2016).

DIN 07652621
Primary Designation Director
Industry Pharma
First Appointment 16 Dec 2016
Oldest Company Age 20 yrs
Largest company Alkon Formulation Private Limited · ₹7.74 Cr (FY 2024)
Combined revenue ₹9.39 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Alkon Formulation Private Limited U74999HP2017PTC006450
Director12 Jan 20172017₹7.74 Cr (FY 2024)Active
Director07 Mar 20222006₹1.66 Cr (FY 2024)Active
Saksham Parenteral Private Limited U46497UT2026PTC022148
Director25 Aug 20262026Active
Sunlife Biosciences Limited U21002HP2024PLC011228
Director05 Nov 20242024Active
Innocosmetica Wellness Limited U20237DL2024PLC428252
Director13 Mar 20242024Active
Septy Biosciences Private Limited U24230HP2022PTC009448
Managing Director18 Jul 20222022Active
Director12 Aug 20202020Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Almech India Private Limited U29190HP2016PTC006417
Director16 Dec 20162016Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Septy Biosciences Private Limited
Septy Pharmaceuticals Private Limited
Anjushree Lifescience Private Limited
Almech India Private Limited
Premium access

Shareholding and investment profile for Suresh Chand Saini

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Suresh Chand Saini

Suresh Chand Saini currently holds 7 directorships: Alkon Formulation Private Limited (Director, since 12 Jan 2017, revenue ₹7.74 Cr (FY 2024)); Septy Pharmaceuticals Private Limited (Director, since 07 Mar 2022, revenue ₹1.66 Cr (FY 2024)); Saksham Parenteral Private Limited (Director, since 25 Aug 2026); Sunlife Biosciences Limited (Director, since 05 Nov 2024); Innocosmetica Wellness Limited (Director, since 13 Mar 2024); and 2 more.

Suresh Chand Saini was first appointed on 16 Dec 2016 as Director at Almech India Private Limited. The most recent appointment on record is 25 Aug 2026 at Saksham Parenteral Private Limited.

The 2 current companies of Suresh Chand Saini that report revenue have a combined latest revenue of ₹9.39 Cr: Alkon Formulation Private Limited ₹7.74 Cr (FY 2024); Septy Pharmaceuticals Private Limited ₹1.66 Cr (FY 2024).

Suresh Chand Saini held 1 earlier board appointment: Almech India Private Limited (Director, from 16 Dec 2016).

The current boards of Suresh Chand Saini's companies include Anju Kumari (Alkon Formulation Private Limited), Malvir Singh (Saksham Parenteral Private Limited), Rubi Rani (Saksham Parenteral Private Limited), Vikas Tripathi (Sunlife Biosciences Limited), Bebi (Innocosmetica Wellness Limited), Balbir Singh (Anjushree Lifescience Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available